Saturday 17 October 2026 Export NAGE’s income statement to Excel — free account

Niagen Bioscience, Inc.

Niagen Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.4 million, up 29.9% from fiscal 2024. In the quarter to June 2026, revenue fell 4.28%, EPS fell 80.0% and free cash flow grew 140.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

2.49 0.09 −3.49%

Follow NAGE

Alert me

Market cap: $204.2M
P/E: 12.5×
Fwd P/E: 15.0×
Dividend yield: —
F-score: 6/9
Altman Z: 10.54
Beneish M: −1.55
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.05

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 34.49%

Capital & Financial Ratios $m

Market Cap 204.15

Revenue 129.08

Net Income 15.99

Free Cash Flow 11.47

Net Debt (66.74)

Current Ratio 6.50

Debt/Equity 0.00

P/E ratio 12.45

Fwd P/E 15.00

P/S ratio 1.53

P/B ratio 2.39

Past 5Y EPS Growth —

This Y EPS Growth (35.40%)

Next Y EPS Growth (4.83%)

Next Y revenue growth 2.92%

Next 5Y EPS Growth (2.27%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 9.84%

10-year low 10-year high

P/B against its own 10 years 0.04%

10-year low 10-year high

EV/Sales against its own 10 years 3.24%

10-year low 10-year high

EV/FCF against its own 10 years 0.48%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	27	45	65	67
Receivables	5	8	10	9
Inventory	15	9	20	21
Other	—	—	1	—
	50	64	97	98

	2023	2024	2025	Q'26
Payables	10	9	11	9
ST’ Debt	—	—	—	—
Other	0	1	0	0
	21	18	20	15

Compound Annual Growth %

	10y	5y	3y
Sales	21.89%	16.91%	21.56%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	30.67%	36.04%	38.72%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	31	30	—	—	—
’25	30	31	34	34	129
’24	22	23	26	29	100
’23	23	20	19	21	84
’22	17	17	17	21	72
’21	15	18	17	18	67
’20	14	15	14	15	59

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	3	—	—	—
’25	8	1	4	1	14
’24	0	0	3	9	12
’23	3	3	0	1	7
’22	(7)	(4)	(4)	0	(15)
’21	(5)	(8)	(6)	(5)	(24)
’20	(5)	(2)	(4)	0	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	5	3	—	—	—
’25	8	1	4	1	13
’24	0	0	3	9	12
’23	3	3	0	1	7
’22	(7)	(4)	(4)	0	(15)
’21	(5)	(8)	(6)	(5)	(25)
’20	(5)	(2)	(4)	0	(11)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.07	0.01	—	—	—
’25	0.06	0.04	0.05	0.05	0.20
’24	(0.01)	0.00	0.02	0.09	0.11
’23	(0.03)	(0.03)	(0.01)	0.00	(0.07)
’22	(0.11)	(0.09)	(0.01)	(0.02)	(0.24)
’21	(0.12)	(0.08)	(0.13)	(0.08)	(0.40)
’20	(0.10)	(0.06)	(0.07)	(0.10)	(0.33)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2.25	2.26	2.79	2.68	2.50	3.70	1.15	1.25	1.36	5.16	Analyst estimates 2026–2028 Powerpack
	High	6.18	7.24	6.63	4.95	6.00	23.66	4.03	2.24	7.97	14.69
People
People	Employees	93	74	100	110	110	115	113	106	104	117
	Revenue/emp, $m	0.23	0.29	0.32	0.42	0.54	0.59	0.64	0.79	0.96	1.11
Income, $m
Income, $m	Revenue	22	21	32	46	59	67	72	84	100	129
	Gross margin, %	47.96	49.42	50.88	55.67	59.53	61.51	59.40	60.76	61.84	64.28
	EBT	(4)	(17)	(33)	(32)	(20)	(27)	(17)	(5)	9	18
	EBT margin, %	(16.39)	(77.97)	(105.57)	(69.45)	(33.62)	(40.22)	(22.96)	(5.91)	8.89	14.06
	Net income	(3)	(11)	(33)	(32)	(20)	(27)	(17)	(5)	9	17
	Depreciation	0	1	1	2	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	0.58	0.48	0.57	0.81	0.97	1.00	1.03	1.11	1.31	1.63
	Earnings	(0.08)	(0.26)	(0.61)	(0.56)	(0.33)	(0.40)	(0.24)	(0.07)	0.11	0.22
	Cash flow	(0.08)	(0.22)	(0.38)	(0.36)	(0.17)	(0.36)	(0.22)	0.09	0.16	0.17
	Capex	(0.05)	0.10	(0.03)	0.00	0.00	(0.01)	0.00	0.00	0.00	0.00
	Free cash flow	(0.12)	(0.12)	(0.41)	(0.36)	(0.18)	(0.37)	(0.22)	0.09	0.16	0.17
	Book value	0.27	1.21	0.49	0.36	0.27	0.47	0.41	0.38	0.61	0.97
	Shares, m	37	45	55	57	61	67	70	75	76	79
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	51.40	27.65
	P/S	5.94	13.36	5.98	5.31	4.95	3.73	1.64	1.28	4.05	3.89
	P/B	12.90	5.26	6.94	12.03	17.85	7.92	4.11	3.77	8.75	6.58
	EV/Sales	5.97	11.32	5.33	4.95	4.70	3.40	1.38	0.98	3.62	3.40
	EV/FCF	(27.72)	(46.13)	(7.52)	(11.09)	(25.91)	(9.32)	(6.43)	11.76	30.16	33.40
Cash, $m
Cash, $m	Operating cash flow	(3)	(10)	(21)	(20)	(11)	(24)	(15)	7	12	14
	Capex	(2)	5	(1)	0	0	0	0	0	0	0
	Free cash flow	(5)	(5)	(22)	(21)	(11)	(25)	(15)	7	12	13
Balance, $m
Balance, $m	Working capital	7	49	22	18	16	31	29	29	46	77
	Total debt	0	0	0	0	0	4	0	0	—	—
	Net debt	(1)	(45)	(22)	(19)	(17)	(24)	(20)	(27)	(45)	(65)
	Shareholders’ equity	10	54	27	20	16	32	29	28	46	77
Returns, %
Returns, %	ROA	(15.21)	(27.59)	(63.49)	(77.95)	(50.70)	(56.40)	(29.56)	(9.06)	13.88	19.90
	ROIC	(20.93)	(116.91)	(441.21)	(1,184.89)	0.00	(220.84)	(141.07)	(306.16)	336.73	86.63
	ROE	(38.40)	(35.66)	(82.25)	(135.01)	(108.09)	(112.68)	(54.77)	(17.29)	22.94	28.35

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IFRX InflaRx N.V.	$212.2M	— (loss-making)	— (loss-making)	−128.93% (below 0%: shrinking)	n/m	+69.33% (above 0%: growing)	14,029.95%	0.00%	Compare
ZNTL Zentalis Pharmaceuticals, Inc.	$212.1M	— (loss-making)	— (loss-making)	—	n/m	−9.06% (below 0%: shrinking)	100.00%	0.00%	Compare
LRMR Larimar Therapeutics, Inc.	$206.7M	— (loss-making)	—	—	n/m	−127.63% (below 0%: shrinking)	0.00%	0.00%	Compare
PRQR ProQR Therapeutics N.V.	$204.6M	— (loss-making)	— (loss-making)	+135.03% (above 0%: growing)	n/m	−1.06% (below 0%: shrinking)	100.00%	(100.72%)	Compare
NAGE Niagen Bioscience, Inc.	$204.2M	12.5×	15.0×	−4.28% (below 0%: shrinking)	−80.00% (below 0%: shrinking)	+140.63% (above 0%: growing)	64.84%	2.35%
LYEL Lyell Immunopharma, Inc.	$200.7M	— (loss-making)	— (loss-making)	−50.00% (below 0%: shrinking)	n/m	+1.31% (above 0%: growing)	100.00%	(1,183,425.00%)	Compare
RNAC Cartesian Therapeutics, Inc.	$199.1M	— (loss-making)	— (loss-making)	−92.91% (below 0%: shrinking)	−7.84% (below 0%: shrinking)	−6.15% (below 0%: shrinking)	100.00%	0.00%	Compare
IVVD Invivyd, Inc.	$197.1M	— (loss-making)	— (loss-making)	+21.20% (above 0%: growing)	n/m	−226.89% (below 0%: shrinking)	91.09%	(320.76%)	Compare
CGEN Compugen Ltd.	$197.0M	5.2×	— (loss-making)	+107.00% (above 0%: growing)	n/m	−155.42% (below 0%: shrinking)	(3.54%)	(339.62%)	Compare
Median of peers	$202.7M	—	—	−14.40%	—	−7.60%	100.00%	(50.36%)

All 614 Biotechnology stocks →

Niagen Bioscience, Inc. (NAGE) key facts

Strength: Niagen Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.4 million, up 29.9% from fiscal 2024.
Niagen Bioscience, Inc. (NAGE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NAGE traded at $2.49, a market capitalization of $204.2 million.
Return on equity was 28.4% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 10.54 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.